Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma, PMID: 31693429
Polatuzumab Vedotin: First Global Approval, PMID: 31352604
Polatuzumab Vedotin: a New Target for B Cell Malignancies, PMID: 32172360
Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma, PMID: 32700972
An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma, PMID: 32700586
Polatuzumab vedotin for B-cell lymphoma, PMID: 33363310
Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data, PMID: 32606733
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS), PMID: 30935953
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study, PMID: 31101489
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab, PMID: 32309823
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study, PMID: 25925619
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis, PMID: 33431309
Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience, PMID: 32981410
Antibodies to watch in 2020, PMID: 31847708
Polatuzumab Vedotin Approved for DLBCL, PMID: 31242994
Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma, PMID: 32954807
Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma, PMID: 32705923
Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, PMID: 32500753
Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study, PMID: 33029633
Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin, PMID: 32985934
Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients, PMID: 32974076
Correction to: Polatuzumab Vedotin: First Global Approval, PMID: 31617142
Excellent Interim Treatment Response with Polatuzumab Vedotin, PMID: 32608220
Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma, PMID: 31770050
Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma, PMID: 32835553
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, PMID: 33202794
Antibodies to watch in 2019, PMID: 30516432
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma, PMID: 32222808
US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma, PMID: 33028076
Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials, PMID: 33205435
Recent advances of antibody drug conjugates for clinical applications, PMID: 33088681
Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin, PMID: 31270798
Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients, PMID: 33230948
Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies, PMID: 32521386
Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma, PMID: 33047089
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma, PMID: 31749251
Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma, PMID: 31548805
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma, PMID: 32715803
Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes, PMID: 25708834
ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma, PMID: 32421455
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma, PMID: 33258982
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, PMID: 32770353
A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma, PMID: 33001384
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas, PMID: 34196677
Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY ®) Antibody-Drug Conjugate in Sprague Dawley Rats, PMID: 33806916
Time-to-Event Analysis of Polatuzumab Vedotin-Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens, PMID: 28544534
Pharmaceutical Approval Update, PMID: 31485143
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma, PMID: 27416486
Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), PMID: 25768997
Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy, PMID: 33719894
The Silence of the Lambdas: Hidden Complexities in the Evolution of Double-Hit Lymphomas., PMID:40526040
Heavily Pretreated Refractory Diffuse Large B-Cell Lymphoma Successfully Treated with Epcoritamab: Case Report., PMID:40524964
Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma., PMID:40523447
Adverse cardiac events associated with antibody drug conjugates in cancer patients: a retrospective analysis on the FAERS database and randomized controlled trials., PMID:40455883
Management of Diffuse Large B-Cell Lymphoma as Post-Transplant Lymphoproliferative Disorder in a Kidney Transplant Recipient: A Case Report., PMID:40407632
B cell receptor silencing reveals origin and dependencies of high-grade B cell lymphomas with MYC and BCL2 rearrangements., PMID:40402557
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's Macroglobulinemia., PMID:40382198
Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL., PMID:40377673
Combined Impact of Prior Polatuzumab Vedotin Plus Bendamustine and Rituximab Therapy and Myeloablative Conditioning on Early Post-Transplant BK Virus-Associated Hemorrhagic Cystitis., PMID:40336921
Glofitamab with Polatuzumab Vedotin in Refractory Burkitt's Lymphoma., PMID:40305722
Contemporary management of diffuse large B-cell lymphoma in Japan., PMID:40192055
Broadening the Therapeutic Window of ADCs Using Site-Specific Bioconjugation Showcased by an MMAE-Containing Peptide Linker in a CD79b-Targeting ADC., PMID:40177869
Budget impact of introducing glofitamab for treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy in the United States., PMID:40163049
An aggressive case of Fluid overload-associated large B-cell lymphoma (FO-LBCL) with CD20 down-regulation., PMID:40159287
Loncastuximab Tesirine Versus Polatuzumab Vedotin Plus Bendamustine and Rituximab in Relapsed/Refractory DLBCL After ≥ 2 Lines of Therapy: Matching-Adjusted Indirect Comparison., PMID:40153222
Real-world data of polatuzumab vedotin with bendamustine and rituximab for Japanese relapsed and refractory DLBCL: a multicenter retrospective study., PMID:40134133
Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR-T Therapy., PMID:40110072
Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study., PMID:40085955
Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database., PMID:40041494
Gastrointestinal toxicity of antibody-drug conjugates: a pharmacovigilance study using the FAERS database., PMID:40033454
Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present., PMID:40004173
Polatuzumab vedotin and bendamustine (Pola-B) was effective for refractory CD20-negative double-expressor lymphoma., PMID:39976690
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma., PMID:39966020
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study., PMID:39908481
Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysis., PMID:39907880
Polatuzumab vedotin extravasation injury: a case report., PMID:39862062
[CAR-T therapy in elderly patients with relapsed/refractory diffuse large B-cell lymphoma. Clinical case of the San Martino Hospital in Genoa]., PMID:39840881
Is first-line treatment with polatuzumab vedotin-rituximab-cyclophosphamide, doxorubicin and prednisone (pola-R-CHP) for previously untreated diffuse large B-cell lymphoma cost-effective in China? A cost-effectiveness analysis using a Markov model., PMID:39832983
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma., PMID:39798075
Efficacy and safety of polatuzumab-vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: A systematic review and meta-analysis., PMID:39793679
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients., PMID:39792424
The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma., PMID:39767565
Successful Treatment of Methotrexate-associated Lymphoproliferative Disorder with the Pola-R-CHP Regimen., PMID:39757000
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis., PMID:39657136
Antibody-Drug Conjugates: The Toxicities and Adverse Effects That Emergency Physicians Must Know., PMID:39641680
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study., PMID:39641321
SOHO State of the Art Updates and Next Questions | Diffuse Large B-Cell Lymphoma in Older Adults: A Comprehensive Review., PMID:39613700
Primary Thyroid Lymphoma: A Rare Diagnosis Treated With Polatuzumab Vedotin., PMID:39548855
Real-world outcomes of diffuse large B-cell lymphoma treated with frontline R-CHOP(-like) regimens in an Asian multi-ethnic population., PMID:39542909
[Treatment of refractory diffuse large B-cell lymphoma involving the central nervous system with polatuzumab vedotin-based regimen: a case report and literature review]., PMID:39414613
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell Lymphomas., PMID:39404868
[Recent advances in the treatment of DLBCL]., PMID:39358300
Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease., PMID:39353813
How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma., PMID:39356892
Imaged Capillary Isoelectric Focusing Coupled to High-Resolution Mass Spectrometry (icIEF-MS) for Cysteine-Linked Antibody-Drug Conjugate (ADC) Heterogeneity Characterization Under Native Condition., PMID:39347563
The current landscape of frontline large B-cell lymphoma trials., PMID:39316716
Pharmacovigilance study of the association between peripheral neuropathy and antibody-drug conjugates using the FDA adverse event reporting system., PMID:39271716
Tuning Responses to Polatuzumab Vedotin in B-cell Lymphoma., PMID:39228298
[The Utility of Primary Prophylaxis with Pegfilgrastim in Combination with Polatuzumab Vedotin Therapy]., PMID:39191692
[Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development]., PMID:39191681
For research use only. Not for human or drug use.
